Longevity Genetic Panel

Comprehensive genetic testing analysing variants associated with longevity, disease risk, metabolic function, and pharmacogenomics to guide personalised longevity medicine protocols.

Genetic testing for longevity medicine analyses an individual's DNA for variants that influence biological ageing, disease susceptibility, metabolic efficiency, and response to specific interventions. Unlike direct-to-consumer genetic tests, clinical longevity genetics panels are interpreted within a medical framework — translating raw variant data into actionable protocols that a longevity physician can implement. At Lifespan Asia, genetic testing encompasses analysis of key longevity-relevant gene categories. APOE genotyping establishes Alzheimer's and cardiovascular risk stratification. MTHFR and related methylation pathway variants inform B-vitamin supplementation and homocysteine management strategies. Telomere-related genes including TERT and TERC variants provide context for biological age trajectory. Mitochondrial DNA variants affecting energy metabolism and ageing rate are assessed alongside nuclear genome variants relevant to oxidative stress response, inflammation, and DNA repair capacity. Pharmacogenomic analysis — examining how an individual metabolises specific compounds through CYP450 enzyme variants — is particularly valuable for clients considering peptide therapy, hormone optimisation, or NAD+ precursor supplementation, as it enables precise dosing and avoids ineffective or adverse protocols. Sample collection at Lifespan Asia is typically via saliva or blood draw, with analysis conducted by accredited genomics laboratories. Results are returned within two to four weeks and reviewed with the client in a dedicated genetic counselling consultation. This interpretation session translates findings into a prioritised longevity action plan, integrating genetic insights with biomarker data from micronutrient and inflammation panels to build a comprehensive health roadmap.